Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: ICU Medical develops, manufactures, and markets disposable medical devices, primarily for intravenous (I.V.) therapy and critical care. The company operates principally in one segment and relies heavily on a strategic relationship with Hospira, Inc., which accounted for approximately 77% of total revenue in the first nine months of 2006. Key product lines include the CLAVE connector system, custom I.V. systems, and critical care devices produced under a 20-year Manufacturing, Commercialization and Development Agreement (MCDA) with Hospira.
Key Financial Metrics
| Financial Metric (in thousands) | Three Months Ended Sep 30, 2006 |
Three Months Ended Sep 30, 2005 |
Nine Months Ended Sep 30, 2006 |
Nine Months Ended Sep 30, 2005 |
|---|---|---|---|---|
| Total Revenue | $48,600 | $46,524 | $148,806 | $114,302 |
| Net Sales | $48,097 | $46,121 | $146,445 | $111,900 |
| Gross Profit | $18,850 | $19,276 | $63,274 | $50,834 |
| Gross Margin (of Net Sales) | 39.2% | 41.8% | 43.2% | 45.4% |
| Net Income | $6,142 | $5,807 | $18,800 | $14,963 |
| Diluted EPS | $0.39 | $0.39 | $1.21 | $1.00 |
| Cash from Operating Activities | N/A | N/A | $17,253 | $20,352 |
| Cash & Liquid Investments | $105,501 | N/A | $105,501 | N/A |
Note: Gross margin percentages calculated based on Net Sales as per management discussion.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4.5% in the third quarter and 30.2% year-to-date compared to the prior year periods. The nine-month increase was driven primarily by the inclusion of critical care products under the MCDA with Hospira for a full year and growth in custom I.V. systems.
- Customer Concentration: Sales to Hospira remained dominant, representing 76% of revenue in Q3 2006 and 77% for the nine months ended September 30, 2006. Sales to Hospira under the MCDA were $56.2 million for the nine months, compared to $29.8 million in the prior year period.
- Margin Pressure: Gross margins declined slightly in the third quarter (39.2% vs 41.8% prior year) due to approximately $3.0 million in non-recurring costs associated with relocating manufacturing from San Clemente to Salt Lake City, including unabsorbed overhead and severance.
- Unusual Items: The company recognized a $2.1 million gain on the sale of a manufacturing building in San Clemente, which was no longer needed following the relocation of operations.
- Stock-Based Compensation: The company adopted SFAS 123(R) on January 1, 2006, resulting in the recognition of stock-based compensation expense ($0.3 million for the nine months ended Sep 30, 2006), which reduced net income by approximately $0.02 per share.
Guidance, Outlook, and Risks
- Outlook: Management expects gross margins to improve in the fourth quarter of 2006 as non-recurring relocation costs cease. SG&A expenses are expected to be approximately 22% to 24% of revenue for the full year 2006.
- Capital Expenditures: Estimated capital expenditures for 2006 are approximately $20.0 million, including facility improvements in Salt Lake City and Mexico.
- Treasury Stock: The company adopted a plan to purchase up to $2.0 million initially, then up to $1.0 million monthly for a year. $4.0 million was purchased in Q3, with an expectation to purchase up to $3.0 million more in Q4.
- Key Risks:
- Hospira Dependence: A significant portion of sales depends on Hospira; any deterioration in this relationship or Hospira's market position could materially harm the company.
- Relocation Risks: Ongoing moves of manufacturing to Salt Lake City and Mexico pose risks of production interruptions and quality issues.
- Competition & Patents: The company faces litigation regarding patent infringement (e.g., against Alaris/Cardinal) and risks of competitors developing superior products. A recent court order interpreting patent claims could impair enforcement capabilities.
- Raw Material Costs: Exposure to rising petroleum-based resin prices and transportation costs.
Investor Verification Checklist
- Verify the sustainability of the 77% revenue concentration with Hospira and the terms of the MCDA regarding cost savings and pricing.
- Confirm the completion status of the manufacturing relocation from San Clemente/Connecticut to Salt Lake City and Mexico, and monitor for any production delays.
- Review the status of the patent litigation against Alaris Medical Systems (Cardinal Health) and the impact of the July 2006 court order on future enforcement.
- Monitor the execution of the treasury stock repurchase plan and its impact on cash reserves.
- Assess the impact of rising raw material (resin) and energy costs on future gross margins, given the company's limited ability to pass costs to customers.